** LTR Pharma LTP rises as much as 7.5% to A$0.50, highest since November 27
** Biopharmaceutical firm gets regulatory clearance from Therapeutic Goods Administration for its SPONTAN Phase II clinical study
** Says study expected to generate prescribing insights for physicians treating older men
** About 478,000 shares traded, 1.9x the 30-day avg
** LTP last up 3.2%, trimming YTD losses to 40.7%
